TriVascular Technologies, manufacturer of the Ovation Prime abdominal stent graft system, announced that is has filed a registration statement on Form S-1 with the US Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. TriVascular has applied to list its common stock on the NASDAQ Global Market under the ticker symbol “TRIV.”
J P Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint bookrunning managers for the offering. Canaccord Genuity Inc and Stifel, Nicolaus & Company, Incorporated are acting as co-managers.
A registration statement relating to the securities has been filed with the Securities and Exchange Commission, but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
